These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7195923)

  • 1. Cis-platinum associated hearing loss.
    Rybak LP
    J Laryngol Otol; 1981 Jul; 95(7):745-7. PubMed ID: 7195923
    [No Abstract]   [Full Text] [Related]  

  • 2. The "plateau effect" of cis-platinum-induced hearing loss.
    Myers SF; Blakley BW; Schwan S; Rintelmann WF; Mathog RH
    Otolaryngol Head Neck Surg; 1991 Jan; 104(1):122-7. PubMed ID: 1900608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythromycin associated hearing loss in a patient with prior cis-platinum induced ototoxicity.
    Wallach PM; Love SR; Fiorica JV; Hoffman MS; Flannery MT
    J Fla Med Assoc; 1992 Dec; 79(12):821-2. PubMed ID: 1474367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cis-platinum ototoxicity in children.
    Weatherly RA; Owens JJ; Catlin FI; Mahoney DH
    Laryngoscope; 1991 Sep; 101(9):917-24. PubMed ID: 1886439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone-conduction speech reception thresholds with the mentally retarded.
    Johnson CW; Bordenick RM
    J Aud Res; 1978 Jul; 18(3):229-35. PubMed ID: 755820
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cisplatin ototoxicity. A clinical study].
    Schröder M; Laskawi R; Stennert E; Kühnle H; Thiele FW
    Laryngol Rhinol Otol (Stuttg); 1986 Feb; 65(2):86-9. PubMed ID: 3959692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
    Waissbluth S; Del Valle Á; Chuang A; Becker A
    Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profound hearing loss from intravertebral artery cisplatin.
    Wetmore SJ; Koike KJ; Bloomfield SM
    Otolaryngol Head Neck Surg; 1997 Feb; 116(2):234-7. PubMed ID: 9051071
    [No Abstract]   [Full Text] [Related]  

  • 9. [Ototoxicity exemplified by aminoglycosides and cisplatin: is there a specific antidote].
    Dieler R; Shehata-Dieler WE
    HNO; 1994 Sep; 42(9):525-8. PubMed ID: 7989223
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of fluctuating noise and interfering speech on the speech-reception threshold for impaired and normal hearing.
    Festen JM; Plomp R
    J Acoust Soc Am; 1990 Oct; 88(4):1725-36. PubMed ID: 2262629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Measuring the frequency resolution capacity of hearing in the normal state and in neurosensory hearing loss].
    Novikova LA; Rybalko NV; Supin AIa
    Vestn Otorinolaringol; 1986; (6):26-31. PubMed ID: 3811111
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical study of the ototoxicity of cisplatin].
    Basterra J; Iranzo C; Marco J
    An Otorrinolaringol Ibero Am; 1985; 12(2):167-72. PubMed ID: 4039901
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of attention on the speech reception threshold and pupil response of people with impaired and normal hearing.
    Koelewijn T; Versfeld NJ; Kramer SE
    Hear Res; 2017 Oct; 354():56-63. PubMed ID: 28869841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring hearing during ototoxic cisplatin therapy].
    Kluba J; Kluba U; von Specht H; Mittler U
    Padiatr Grenzgeb; 1990; 29(1):19-23. PubMed ID: 2342815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
    J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study.
    Low WK; Toh ST; Wee J; Fook-Chong SM; Wang DY
    J Clin Oncol; 2006 Apr; 24(12):1904-9. PubMed ID: 16622266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery from cisplatin-induced ototoxicity: a case report and review.
    Truong MT; Winzelberg J; Chang KW
    Int J Pediatr Otorhinolaryngol; 2007 Oct; 71(10):1631-8. PubMed ID: 17706797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring the threshold for speech reception by adaptive variation of the signal bandwidth. II. Hearing-impaired listeners.
    Noordhoek IM; Houtgast T; Festen JM
    J Acoust Soc Am; 2000 Mar; 107(3):1685-96. PubMed ID: 10738821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive abilities relate to self-reported hearing disability.
    Zekveld AA; George EL; Houtgast T; Kramer SE
    J Speech Lang Hear Res; 2013 Oct; 56(5):1364-72. PubMed ID: 23838985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative adverse effect profiles of platinum drugs.
    McKeage MJ
    Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.